Innovative technology of prostate diagnostic imaging
Last updated date: 16-Jul-2021
3 mins read
As the population ages, a steady increase in the number of diagnoses of prostate cancer is observed. We can already speak of an epidemic of prostate cancer - it is currently the most common cancer in men in Europe. In Poland, this cancer is diagnosed in 16,000 men each year, and the number increases every year.
With access to modern operating technology, including the Da Vinci robot and the Ablatherm HIFU robot at the HIFU CLINIC Prostate Cancer Treatment Center, preoperative diagnostics is playing an increasingly important role.
Owing to the fusion biopsy technology, magnetic resonance and ultrasound images combine, allowing unprecedented precision to hit even a few millimeters of prostate cancer. In the case of traditional methods, based on ultrasound, such small cancer foci were often not visible. Currently, the precision of the new method - prostate fusion biopsy - reaches even 2 mm.
The use of a fusion biopsy allows both - the detection of clinically significant early stage prostate cancer and a reduction in the detection of clinically insignificant prostate cancers.
Fusion biopsy focused on magnetic resonance imaging allows the urologist and the patient to make an informed decision about the need for intervention or active supervision in the case of prostate cancer – says doctor Stefan W. Czarniecki, urologist, head of the Urology Department at the Carolina Medical Center. – However, a parallel breakthrough is to perform this procedure safely, transperineally (through the skin of the perineum), and not with rectal access as in the case of traditional biopsy, which reduces the risk of sepsis to <0.01%. It is also very important that the procedure is performed under intravenous anesthesia, which allows for precise and painless collection of samples – adds specialist.
The purpose of using fusion biopsy technology when we suspect prostate cancer is to increase the likelihood of curing cancer detected at an early stage, but also to identify those patients who can benefit from targeted therapies, which save the gland – says Marek Filipek, MD, PhD, urologist, medical director of HIFU CLINIC.
Fusion biopsy technology is based on the combination of a previously performed magnetic resonance image of the prostate with an ultrasound image obtained "live" during the procedure. This is to create an extremely accurate three-dimensional topographic map of the gland, which in turn allows for highly accurate identification and collection of samples. The procedure lasts for a half an hour and takes place under intravenous anesthesia, during a 2.5-hour stay in the hospital ward.
Benefits of transperineal fusion biopsy
- It enables precise collection of specimens from even a few millimeter changes in the prostate, displayed in highly sensitive magnetic resonance imaging. This allows patients to make sure the diagnosis is correct, and doctors to correctly diagnose even the smallest cancer;
- It allows to avoid repeating a traditional biopsy, providing a high-quality response from the first conduction;
- It dramatically reduces the risk of the most severe complication of traditional rectal biopsy, which is sepsis.
Candidates for percutaneous (transperineal) fusion prostate biopsy are:
men qualified for traditional biopsy who are concerned about its complications;
men with elevated PSA (parameter depending on age> 1.2 or 4 ng / ml);
men who have already undergone a traditional biopsy but are still suspected of having prostate cancer;
men who are already diagnosed with prostate cancer - to verify the diagnosis.